Patents by Inventor Yuzhe Peng

Yuzhe Peng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240307442
    Abstract: Embodiments relate to a modified cell comprising a polynucleotide encoding an antigen binding molecule and a polynucleotide encoding an agent targeting one or more extracellular matrix (ECM) molecules. In embodiments, the polynucleotide encoding the agent comprises at least a nucleic acid encoding Cathepsin K (CK), a nucleic acid encoding Neutrophil Elastase (NE), or a nucleic acid encoding MMP7. In embodiments, the nucleic acid encoding NE comprises a nucleic acid encoding NE and a nucleic acid encoding a signaling domain of IL2. In embodiments, expression of the polynucleotide encoding the agent is regulated by hypoxia-inducible factor 1-alpha (HIF1?), nuclear factor of activated T-cells (NFAT), forkhead box P3 (FOXP3), or nuclear factor kappa B (NF-?B).
    Type: Application
    Filed: June 16, 2022
    Publication date: September 19, 2024
    Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Wei DING, Yang ZHAO, Guiting HAN, Yuzhe PENG, Xianyang JIANG, Zhiyuan CAO, Lei XIAO, Le TIAN
  • Patent number: 11970548
    Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: April 30, 2024
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Zhiyuan Cao, Yuzhe Peng, Lei Xiao, Zhao Wu, Le Tian
  • Patent number: 11944645
    Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: April 2, 2024
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Zhiyuan Cao, Lei Xiao, Yuzhe Peng, Wei Ding, Wensheng Wang
  • Publication number: 20240024476
    Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.
    Type: Application
    Filed: January 6, 2022
    Publication date: January 25, 2024
    Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Wensheng Wang, Beibei Jia, Dongqi Chen, Xiaoqiang Xu, Xudong Tang, Wei Ding, Xianyang Jiang, Yuzhe Peng, Guiting Han, Le Tian, Zhao Wu, Lei Xiao
  • Publication number: 20230074145
    Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.
    Type: Application
    Filed: August 23, 2022
    Publication date: March 9, 2023
    Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Zhiyuan Cao, Yuzhe Peng, Lei Xiao, Zhao Wu, Le Tian
  • Publication number: 20220105134
    Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
    Type: Application
    Filed: September 30, 2021
    Publication date: April 7, 2022
    Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
    Inventors: Zhiyuan Cao, Lei Xiao, Yuzhe Peng, Wei Ding, Wensheng Wang